While we know that reduced bone density is a risk factor for osteoporotic fractures, we also know that many of the anti-resorptive treatments do not appreciably increase bone density. Is maintenance of bone density adequate to prevent recurrent fragility fractures?
Recent data suggests that bone resorption releases muscle catabolic factors in several conditions and that these contribute to muscle loss and weakness, which may play a role in repeated falls. The aim of this Research Topic is to focus attention on the role of muscle and muscle wasting in the pathogenesis of osteoporotic fractures.
We seek to gain information on the biomechanical role of muscle on bone in osteoporosis, the role of estrogen in preserving muscle mass and strength, the nervous system's role in maintaining muscle and bone integrity and what happens when neurologic disease, such as spinal cord injury, affects the musculoskeletal system.
We also seek to find out what we can learn from muscle-bone relationships in other disease states that can be applied to the osteoporotic condition and the precise effects of interventional treatment with anti-resorptives and osteoanabolic agents on fracture incidence and recurrence.
What happens to the incidence of falls in osteoporosis treatment? What is the relationship of treatment to sarcopenia? All these issues are likely interrelated and teasing them apart may allow us to develop new therapeutic goals and broaden our concept of osteoporosis.
We aim for submissions of Original Research, and Reviews articles in the following sub-fields:
1. Muscle deficiencies in skeletal diseases: implications for osteoporosis
2. Sarcopenia and muscle weakness: pathogenesis
3. Neuromuscular disease and bone
4. Role of muscle in attainment of peak bone mass
5. Muscle and bone crosstalk: biomechanics and biochemistry
6. Interventions in muscle and bone to improve outcomes of bone diseases and muscle diseases
7. The need for new biomarkers targeting muscle and bone
8. Bone secretory factors liberated during resorption
9. Factors involved in falls
10. Osteoporosis and muscle weakness
11. Anti-resorptives and fracture incidence in osteoporosis
12. Anti-resorptives and muscle strength
13. Current treatments for sarcopenia
While we know that reduced bone density is a risk factor for osteoporotic fractures, we also know that many of the anti-resorptive treatments do not appreciably increase bone density. Is maintenance of bone density adequate to prevent recurrent fragility fractures?
Recent data suggests that bone resorption releases muscle catabolic factors in several conditions and that these contribute to muscle loss and weakness, which may play a role in repeated falls. The aim of this Research Topic is to focus attention on the role of muscle and muscle wasting in the pathogenesis of osteoporotic fractures.
We seek to gain information on the biomechanical role of muscle on bone in osteoporosis, the role of estrogen in preserving muscle mass and strength, the nervous system's role in maintaining muscle and bone integrity and what happens when neurologic disease, such as spinal cord injury, affects the musculoskeletal system.
We also seek to find out what we can learn from muscle-bone relationships in other disease states that can be applied to the osteoporotic condition and the precise effects of interventional treatment with anti-resorptives and osteoanabolic agents on fracture incidence and recurrence.
What happens to the incidence of falls in osteoporosis treatment? What is the relationship of treatment to sarcopenia? All these issues are likely interrelated and teasing them apart may allow us to develop new therapeutic goals and broaden our concept of osteoporosis.
We aim for submissions of Original Research, and Reviews articles in the following sub-fields:
1. Muscle deficiencies in skeletal diseases: implications for osteoporosis
2. Sarcopenia and muscle weakness: pathogenesis
3. Neuromuscular disease and bone
4. Role of muscle in attainment of peak bone mass
5. Muscle and bone crosstalk: biomechanics and biochemistry
6. Interventions in muscle and bone to improve outcomes of bone diseases and muscle diseases
7. The need for new biomarkers targeting muscle and bone
8. Bone secretory factors liberated during resorption
9. Factors involved in falls
10. Osteoporosis and muscle weakness
11. Anti-resorptives and fracture incidence in osteoporosis
12. Anti-resorptives and muscle strength
13. Current treatments for sarcopenia
